{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=19", "query": { "intervention": "Neoadjuvant therapy", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 2079, "total_pages": 208, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T18:08:37.550Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04710498", "title": "Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Squamous Cell Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2021-06-22", "completion_date": "2024-02-15", "has_results": true, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-10-31T18:08:37.550Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04710498" }, { "nct_id": "NCT00491816", "title": "Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Erlotinib with neoadjuvant chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 32, "start_date": "2007-07", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2017-01-19", "last_synced_at": "2026-10-31T18:08:37.550Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00491816" }, { "nct_id": "NCT07552558", "title": "Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "HPV-Negative Squamous Cell Carcinoma" ], "interventions": [ { "name": "Hypofractionated Stereotactic Body Radiotherapy (SBRT)", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Ficerafusp alfa", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2026-09-30", "completion_date": "2033-11-30", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-31T18:08:37.550Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07552558" }, { "nct_id": "NCT05319015", "title": "Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Neoadjuvant Lenvatinib", "type": "DRUG" }, { "name": "Neoadjuvant Pembrolizumab", "type": "DRUG" }, { "name": "Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection", "type": "PROCEDURE" }, { "name": "Adjuvant Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-01-06", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-31T18:08:37.550Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05319015" }, { "nct_id": "NCT01882764", "title": "HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "HMPL-004", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchison Medipharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2013-06", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-10-31T18:08:37.550Z", "location_count": 1, "location_summary": "Agawam, Massachusetts", "locations": [ { "city": "Agawam", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01882764" }, { "nct_id": "NCT01076335", "title": "Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Neoadjuvant Hormonal Therapy", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 40, "start_date": "2005-05", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-09-19", "last_synced_at": "2026-10-31T18:08:37.550Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01076335" }, { "nct_id": "NCT03944915", "title": "De-Escalation Therapy for Human Papillomavirus Negative Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Papilloma Virus", "Squamous Cell Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "HPV-Related Squamous Cell Carcinoma", "HNSCC" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Hydroxyurea Pill", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Filgrastim Injection", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2019-08-26", "completion_date": "2023-11-01", "has_results": true, "last_update_posted_date": "2025-05-11", "last_synced_at": "2026-10-31T18:08:37.550Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03944915" }, { "nct_id": "NCT06050252", "title": "Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Resectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Resection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2024-07-10", "completion_date": "2027-02-12", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-31T18:08:37.550Z", "location_count": 57, "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 47 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Derby", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06050252" }, { "nct_id": "NCT06362252", "title": "A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Extensive Stage-small Cell Lung Cancer" ], "interventions": [ { "name": "Ifinatamab deruxtecan", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2024-07-22", "completion_date": "2028-02-20", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-31T18:08:37.550Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06362252" }, { "nct_id": "NCT00019864", "title": "Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cardiac Toxicity", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "dexrazoxane hydrochloride", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 100, "start_date": "2000-03", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-31T18:08:37.550Z", "location_count": 4, "location_summary": "Bethesda, Maryland • Oklahoma City, Oklahoma • Fort Worth, Texas + 1 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Fort Worth", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019864" } ] }